Tuesday 25 October 2011

Desferal


Desferal is a brand name of deferoxamine, approved by the FDA in the following formulation(s):


DESFERAL (deferoxamine mesylate - injectable; injection)



  • Manufacturer: NOVARTIS

    Approved Prior to Jan 1, 1982

    Strength(s): 500MG/VIAL [RLD][AP]


  • Manufacturer: NOVARTIS

    Approval date: May 25, 2000

    Strength(s): 2GM/VIAL [RLD][AP]

Has a generic version of Desferal been approved?


Yes. The following products are equivalent to Desferal:


deferoxamine mesylate injectable; injection



  • Manufacturer: APP PHARMS

    Approval date: September 15, 2009

    Strength(s): 2GM/VIAL [AP], 500MG/VIAL [AP]


  • Manufacturer: BEDFORD

    Approval date: May 30, 2007

    Strength(s): 2GM/VIAL [AP], 500MG/VIAL [AP]


  • Manufacturer: HOSPIRA

    Approval date: March 17, 2004

    Strength(s): 2GM/VIAL [AP], 500MG/VIAL [AP]


  • Manufacturer: WATSON LABS

    Approval date: March 31, 2006

    Strength(s): 2GM/VIAL [AP], 500MG/VIAL [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Desferal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Desferal.

See also...

  • Desferal Consumer Information (Wolters Kluwer)
  • Desferal Consumer Information (Cerner Multum)
  • Desferal Advanced Consumer Information (Micromedex)
  • Desferal AHFS DI Monographs (ASHP)
  • Deferoxamine Consumer Information (Wolters Kluwer)
  • Deferoxamine Consumer Information (Cerner Multum)
  • Deferoxamine Injection Advanced Consumer Information (Micromedex)
  • Deferoxamine Mesylate AHFS DI Monographs (ASHP)

Sunday 23 October 2011

Trisenox


Trisenox is a brand name of arsenic trioxide, approved by the FDA in the following formulation(s):


TRISENOX (arsenic trioxide - injectable; injection)



  • Manufacturer: CEPHALON

    Approval date: September 25, 2000

    Strength(s): 1MG/ML [RLD]

Has a generic version of Trisenox been approved?


No. There is currently no therapeutically equivalent version of Trisenox available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trisenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,723,351
    Issued: April 20, 2004
    Inventor(s): Raymond P.; Warrell, Jr. & Pier Paolo; Pandolfi & Janice L.; Gabrilove
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:

    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)




  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,855,339
    Issued: February 15, 2005
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:

    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)




  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,861,076
    Issued: March 1, 2005
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:

    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)




  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,884,439
    Issued: April 26, 2005
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:

    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)




  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,982,096
    Issued: January 3, 2006
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:

    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)



See also...

  • Trisenox Consumer Information (Wolters Kluwer)
  • Trisenox Consumer Information (Cerner Multum)
  • Trisenox Advanced Consumer Information (Micromedex)
  • Trisenox AHFS DI Monographs (ASHP)
  • Arsenic Consumer Information (Wolters Kluwer)
  • Arsenic trioxide Consumer Information (Cerner Multum)
  • Arsenic trioxide Intravenous Advanced Consumer Information (Micromedex)
  • Arsenic Trioxide AHFS DI Monographs (ASHP)

Thursday 20 October 2011

Voltaren




In the US, Voltaren (diclofenac systemic) is a member of the drug class nonsteroidal anti-inflammatory agents and is used to treat Ankylosing Spondylitis, Aseptic Necrosis, Back Pain, Frozen Shoulder, Muscle Pain, Osteoarthritis, Pain, Period Pain, Rheumatoid Arthritis and Sciatica.

US matches:

  • Voltaren

  • Voltaren Gel

  • Voltaren Drops

  • Voltaren Enteric-Coated Tablets

  • Voltaren XR Extended-Release Tablets

  • Voltaren Ophthalmic

  • Voltaren Topical

  • Voltaren-XR

  • Voltaren XR

Ingredient matches for Voltaren



Diclofenac

Diclofenac is reported as an ingredient of Voltaren in the following countries:


  • Bosnia & Herzegowina

  • Colombia

  • Ghana

  • Guyana

  • Kenya

  • Libya

  • Nigeria

  • Slovenia

  • Sudan

  • Tanzania

  • Zimbabwe

Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:


  • Argentina

  • Chile

  • Czech Republic

  • Germany

  • Italy

  • Malaysia

  • Mexico

  • Sweden

  • Turkey

Diclofenac hydroxyethylpyrrolidine (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:


  • Germany

Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:


  • Germany

  • Slovakia

Diclofenac resinate (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:


  • Germany

  • Switzerland

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Voltaren in the following countries:


  • Algeria

  • Argentina

  • Australia

  • Austria

  • Belgium

  • Benin

  • Brazil

  • Burkina Faso

  • Cameroon

  • Canada

  • Central African Republic

  • Chad

  • Chile

  • Colombia

  • Congo

  • Cote D'ivoire

  • Croatia (Hrvatska)

  • Czech Republic

  • Denmark

  • Ecuador

  • Estonia

  • Ethiopia

  • Finland

  • Gabon

  • Georgia

  • Germany

  • Greece

  • Guinea

  • Hong Kong

  • Hungary

  • Iceland

  • Indonesia

  • Israel

  • Italy

  • Japan

  • Latvia

  • Lithuania

  • Luxembourg

  • Madagascar

  • Malaysia

  • Mali

  • Malta

  • Mauritania

  • Mauritius

  • Mexico

  • Netherlands

  • New Zealand

  • Niger

  • Norway

  • Oman

  • Peru

  • Philippines

  • Poland

  • Portugal

  • Romania

  • Russian Federation

  • Senegal

  • Serbia

  • Singapore

  • Slovakia

  • South Africa

  • Spain

  • Sri Lanka

  • Sweden

  • Switzerland

  • Taiwan

  • Thailand

  • Togo

  • Turkey

  • United States

  • Venezuela

  • Vietnam

  • Zaire

International Drug Name Search

Wednesday 19 October 2011

Bromocriptine Mesylate




Ingredient matches for Bromocriptine Mesylate



Bromocriptine

Bromocriptine Mesylate (USAN) is known as Bromocriptine in the US.

International Drug Name Search

Glossary

USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday 15 October 2011

Carvedilol Jaba




Carvedilol Jaba may be available in the countries listed below.


Ingredient matches for Carvedilol Jaba



Carvedilol

Carvedilol is reported as an ingredient of Carvedilol Jaba in the following countries:


  • Portugal

International Drug Name Search

Thursday 13 October 2011

Cremor hydrocortisoni PCH




Cremor hydrocortisoni PCH may be available in the countries listed below.


Ingredient matches for Cremor hydrocortisoni PCH



Hydrocortisone

Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Cremor hydrocortisoni PCH in the following countries:


  • Netherlands

International Drug Name Search

Tuesday 11 October 2011

Fosinopril Basics




Fosinopril Basics may be available in the countries listed below.


Ingredient matches for Fosinopril Basics



Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinopril Basics in the following countries:


  • Germany

International Drug Name Search

Sunday 9 October 2011

N-Acetilcisteina La Santé




N-Acetilcisteina La Santé may be available in the countries listed below.


Ingredient matches for N-Acetilcisteina La Santé



Acetylcysteine

Acetylcysteine is reported as an ingredient of N-Acetilcisteina La Santé in the following countries:


  • Colombia

International Drug Name Search

Ciclosterona




Ciclosterona may be available in the countries listed below.


Ingredient matches for Ciclosterona



Progesterone

Progesterone is reported as an ingredient of Ciclosterona in the following countries:


  • Peru

International Drug Name Search

Thursday 6 October 2011

Diphenhydramine/Phenylephrine Strips


Pronunciation: DYE-fen-HYE-dra-meen/FEN-il-EF-rin
Generic Name: Diphenhydramine/Phenylephrine
Brand Name: Examples include Children's Triaminic Cough/Cold Nighttime and Theraflu Cold/Cough Nighttime


Diphenhydramine/Phenylephrine Strips are used for:

Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.


Diphenhydramine/Phenylephrine Strips are an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.


Do NOT use Diphenhydramine/Phenylephrine Strips if:


  • you are allergic to any ingredient in Diphenhydramine/Phenylephrine Strips

  • you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems

  • you are taking sodium oxybate (GHB) or you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Diphenhydramine/Phenylephrine Strips:


Some medical conditions may interact with Diphenhydramine/Phenylephrine Strips. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a fast, slow, or irregular heartbeat

  • if you have a history of asthma; lung problems (eg, emphysema); sleep apnea; adrenal gland problems (eg, adrenal gland tumor); heart problems; high blood pressure; diabetes; heart blood vessel problems; stroke; glaucoma or increased pressure in the eye; a blockage of your bladder, stomach, or intestines; ulcers; trouble sleeping; trouble urinating; an enlarged prostate or other prostate problems; seizures; or thyroid problems

  • if you have a chronic cough or a cough that occurs with a large amount of mucus

Some medical conditions may interact with Diphenhydramine/Phenylephrine Strips. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased

  • Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, indomethacin, MAOIs (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Diphenhydramine/Phenylephrine Strips's side effects

  • Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Diphenhydramine/Phenylephrine Strips

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Diphenhydramine/Phenylephrine Strips

This may not be a complete list of all interactions that may occur. Ask your health care provider if Diphenhydramine/Phenylephrine Strips may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Diphenhydramine/Phenylephrine Strips:


Use Diphenhydramine/Phenylephrine Strips as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Diphenhydramine/Phenylephrine Strips by mouth with or without food.

  • Do not remove the strip from the pouch until you are ready to take Diphenhydramine/Phenylephrine Strips. Make sure that your hands are dry when you open Diphenhydramine/Phenylephrine Strips. Remove and place the strip on the tongue. The strip dissolves quickly (and it can be swallowed with saliva). Diphenhydramine/Phenylephrine Strips may be taken with or without water. Take the strip immediately after opening the pouch. Do not store the strip for future use.

  • If you miss a dose of Diphenhydramine/Phenylephrine Strips, take it as soon as you remember. Continue to take it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use Diphenhydramine/Phenylephrine Strips.



Important safety information:


  • Diphenhydramine/Phenylephrine Strips may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Diphenhydramine/Phenylephrine Strips with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Check with your doctor before you drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Diphenhydramine/Phenylephrine Strips; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

  • Do not take diet or appetite control medicines while you are taking Diphenhydramine/Phenylephrine Strips without checking with your doctor.

  • Diphenhydramine/Phenylephrine Strips has diphenhydramine and phenylephrine in it. Before you start any new medicine, check the label to see if it has diphenhydramine or phenylephrine in it too. This includes topical medicines (eg, creams). If it does or if you are not sure, check with your doctor or pharmacist.

  • Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • If your symptoms do not get better within 5 to 7 days or if they get worse, check with your doctor.

  • If cough persists for more than 1 week or occurs with a fever or persistent headache, contact your doctor. A persistent cough could be a sign of a serious condition.

  • Do not use Diphenhydramine/Phenylephrine Strips for a cough with a lot of mucus. Do not use it for a long-term cough (eg, caused by asthma, emphysema, smoking). However, you may use it for these conditions if your doctor tells you to.

  • Diphenhydramine/Phenylephrine Strips may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Diphenhydramine/Phenylephrine Strips. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Diphenhydramine/Phenylephrine Strips may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Diphenhydramine/Phenylephrine Strips for a few days before the tests.

  • Tell your doctor or dentist that you take Diphenhydramine/Phenylephrine Strips before you receive any medical or dental care, emergency care, or surgery.

  • Use Diphenhydramine/Phenylephrine Strips with caution in the ELDERLY; they may be more sensitive to its effects, especially confusion, dizziness, drowsiness, dry mouth, excitability, low blood pressure, and trouble urinating.

  • Caution is advised when using Diphenhydramine/Phenylephrine Strips in CHILDREN; they may be more sensitive to its effects, especially excitability.

  • Different brands of Diphenhydramine/Phenylephrine Strips may have different dosing instructions for CHILDREN. Follow the dosing instructions on the package labeling. If your doctor has given you instructions, follow those. If you are unsure of the dose to give a child, check with your doctor or pharmacist.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Diphenhydramine/Phenylephrine Strips while you are pregnant. Do not take Diphenhydramine/Phenylephrine Strips in the third trimester of pregnancy. Diphenhydramine/Phenylephrine Strips are found in breast milk. Do not breast-feed while taking Diphenhydramine/Phenylephrine Strips.


Possible side effects of Diphenhydramine/Phenylephrine Strips:


All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness; drowsiness; dry mouth; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision or other vision changes; difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; mood or mental changes; persistent trouble sleeping; restlessness; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; tremor.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Diphenhydramine/Phenylephrine side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; ringing in the ears; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular breathing; unusually fast, slow, or irregular heartbeat.


Proper storage of Diphenhydramine/Phenylephrine Strips:

Store Diphenhydramine/Phenylephrine Strips at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diphenhydramine/Phenylephrine Strips out of the reach of children and away from pets.


General information:


  • If you have any questions about Diphenhydramine/Phenylephrine Strips, please talk with your doctor, pharmacist, or other health care provider.

  • Diphenhydramine/Phenylephrine Strips are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Diphenhydramine/Phenylephrine Strips. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Diphenhydramine/Phenylephrine resources


  • Diphenhydramine/Phenylephrine Side Effects (in more detail)
  • Diphenhydramine/Phenylephrine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Diphenhydramine/Phenylephrine Drug Interactions
  • Diphenhydramine/Phenylephrine Support Group
  • 1 Review for Diphenhydramine/Phenylephrine - Add your own review/rating


Compare Diphenhydramine/Phenylephrine with other medications


  • Cold Symptoms
  • Hay Fever
  • Sinusitis

Locorten Vioform




Locorten Vioform may be available in the countries listed below.


UK matches:

  • Locorten Vioform Ear Drops (Amdipharm plc) (SPC)

Ingredient matches for Locorten Vioform



Clioquinol

Clioquinol is reported as an ingredient of Locorten Vioform in the following countries:


  • New Zealand

  • United Kingdom

Flumetasone

Flumetasone 21-pivalate (a derivative of Flumetasone) is reported as an ingredient of Locorten Vioform in the following countries:


  • New Zealand

  • United Kingdom

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.